CBD gel shows promise for fragile x behaviors in major trial
NCT ID NCT04977986
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a cannabidiol (CBD) gel, called ZYN002, applied to the skin in 215 children, teens, and young adults with Fragile X syndrome. The goal was to see if it could improve behavioral symptoms like irritability and social withdrawal. Participants received either the CBD gel or a placebo for up to 18 weeks. The trial is complete, and results will show if the gel is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cannabidiol (CBD) gel applied to the skin
- What this could lead to
- If it works, this could provide a new option to ease behavioral symptoms in people with Fragile X syndrome.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. CBD may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amnova Clinical Research, LLC
Irvine, California, 92604, United States
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Central States Research
Tulsa, Oklahoma, 74136, United States
-
Children's National Medical center
Washington D.C., District of Columbia, 20010, United States
-
Genetics Clinics Australia
Melbourne, Victoria, 3161, Australia
-
Greenwood Genetic Center
Greenville, South Carolina, 29605, United States
-
Health New Zealand - Te Whatu Ora - Wellington Hospital
Newtown, Wellington Region, 6021, New Zealand
-
Kennedy Krieger Institute
Baltimore, Maryland, 21205, United States
-
King's College
London, United Kingdom
-
Lady Cilento Children's Hospital - South Brisbane
Brisbane, Queensland, 4101, Australia
-
Leicester Clinical Research
Leicester, United Kingdom
-
Manchester University NHS Foundation Trust
Manchester, United Kingdom
-
Penn State Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Rare Disease Research
Atlanta, Georgia, 30318, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Science 37
Culver City, California, 90230, United States
-
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics
New York, New York, 10029, United States
-
Thompson Autism Center CHOC
Orange, California, 92868, United States
-
UC Davis Health System, MIND Institute
Sacramento, California, 95817, United States
-
University of Edinburgh
Edinburgh, United Kingdom
-
University of Miami
Miami, Florida, 33136, United States
-
University of Minnesota Fragile X Clinic (Voyager Clinic)
Minneapolis, Minnesota, 55454, United States
-
University of Mississippi
Jackson, Mississippi, 39216, United States
-
Wellcome HRB Clinical Research Facility
Dublin, Ireland
-
Westmead Children's Hospital
Sydney, New South Wales, 2145, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A common antidepressant may tame anxiety in kids with autism and ADHD — a trial puts it to the test
- Can early parent coaching help infants with rare genetic disorders thrive?
- Experimental drug aims to boost brain function in fragile x syndrome
- Newborn screening study aims to catch rare diseases at birth
- New drug trial aims to ease fragile x symptoms in men
- New drug shows promise for fragile x symptoms in small trial